{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"442,892"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Genomic profile of each cell population using oligonucleotide CGH arrays. Reported as unique probes on the CGH array.","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"NUMBER","populationDescription":"One of the cases that had FFPE blocks for the study.","reportingStatus":"POSTED","timeFrame":"Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months","title":"Unique Probes on the Oligonucleotide CGH Array as a Measure of the Genomic Profile of Each Cell Population.","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"unique probes on the CGH arrays"}